SAN DIEGO , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at
SAN DIEGO , Feb. 2, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at
SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a
Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting San Diego, California – Biocept, Inc., a CLIA-certified laboratory testing company focused on oncology diagnostics, specifically the detection and analysis
Company’s ultra-sensitive and quantitative assays support efforts to develop targeted therapies for cancers driven by a variety of genetic mutations SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data
SAN DIEGO , Nov. 16, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, today announced the presentation of recent analytical
SAN DIEGO , March 20, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the presentation of analytical
SAN DIEGO , Oct. 1, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of
SAN DIEGO , Feb. 21, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the